PAR-25-438: Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2025.
National Institutes of Health offered grants of up to $1.0 million to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on December 9, 2025.
From the official notice on Grants.gov, last changed December 9, 2025. Checked November 7, 2026.
- Award ceiling$1.0 million
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU54
- Clinical trialsOptional
- Funded byNIAID, NICHD, NHLBI
- Median yearly award$351,572
- Typical project length5 years
- U54, Specialized Center Cooperative Agreement. A research center with several projects and shared cores, with substantial NIH involvement. Other open U54 notices.
Projects funded under PAR-25-438 were run by National Institute of Allergy and Infectious Diseases (NIAID, 3 projects), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, 2 projects), National Heart Lung and Blood Institute (NHLBI, 1 project) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, 1 project), and 1 more. Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-25-438 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-24-206 | April 2, 2024 | Closed August 19, 2024 | Closed |
Key dates
| Posted | June 5, 2025 |
|---|---|
| Deadline | December 9, 2025 |
| Archived by Grants.gov | February 7, 2026 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 13 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Higher Education Institutions - Includes all typesPublic/State Controlled Institutions of Higher EducationPrivate Institutions of Higher EducationNonprofits Other Than Institutions of Higher EducationNonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)For-Profit OrganizationsSmall BusinessesFor-Profit Organizations (Other than Small Businesses)Local GovernmentsState GovernmentsCounty GovernmentsCity or Township GovernmentsSpecial District GovernmentsIndian/Native American Tribal Governments (Federally Recognized)Indian/Native American Tribal Governments (Other than Federally Recognized)Federal GovernmentsEligible Agencies of the Federal GovernmentU.S. Territory or PossessionOtherIndependent School DistrictsPublic Housing Authorities/Indian Housing AuthoritiesNative American Tribal Organizations (other than Federally recognized tribal governments)Faith-based or Community-based OrganizationsRegional OrganizationsNon-domestic (non-U.S.) Entities (Foreign Organizations)Foreign OrganizationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $351,572; it allows up to $1.0 million per award.
- Most of the money in the 12 programs behind this notice (71% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The objective of this Notice of Funding Opportunity (NOFO) is to invite new and renewal applications for the Rare Diseases Clinical Research Consortia (RDCRC) that comprise the Rare Diseases Clinical Research Network (RDCRN). The RDCRCs are intended to advance and improve diagnosis, management, and treatment of numerous, rare diseases through highly collaborative, multi-site, patient-centric, translational, and clinical research. Special emphasis will be placed on the early and timely identification of individuals with rare diseases and clinical trial readiness.
Funded under PAR-25-438 so far
NIH funded 8 projects under PAR-25-438 in fiscal 2026, at 8 institutions. The median yearly award was $351,572.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Pilot-Feasibility Core | University of Cincinnati | 2026 | $36,408 |
| Pediatric Bone Marrow Failure Network (pBMFN) | Boston Children's Hospital | 2026 | $1.8 million |
| Administrative Core | Henry Ford Health + Michigan State University Health Sciences | 2026 | $658,263 |
| Pilot and Feasibility | Cincinnati Childrens Hosp Med Ctr | 2026 | $29,864 |
| Consortium for Hereditary Epidermal Differentiation Disorders (CHEDD) | Northwestern University | 2026 | $1.6 million |
| Research Project 1 | Vanderbilt University Medical Center | 2026 | $351,572 |
| Pilot/Feasibility Governance Core | Johns Hopkins University | 2026 | $50,674 |
| Peroxisomal Disorders Consortium | Baylor College of Medicine | 2026 | $1.3 million |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Who has won Cardiovascular Diseases Research grants before
From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 313 | $380 million |
| Brigham & Womens Hospital Inc | Massachusetts | 274 | $374 million |
| Regents of the University of Michigan | Michigan | 277 | $355 million |
| The Trustees of Columbia University in the City of New York | New York | 207 | $335 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 295 | $320 million |
Other programs behind this notice
- Diabetes, Digestive, and Kidney Diseases Extramural Research
- Extramural Research Programs in the Neurosciences and Neurological Disorders
- Child Health and Human Development Extramural Research
- National Center for Advancing Translational Sciences
- Arthritis, Musculoskeletal and Skin Diseases Research
- Human Genome Research
- Oral Diseases and Disorders Research
- Lung Diseases Research
- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-25-438 still open?
No. It closed on December 9, 2025.
Who can apply for Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)?
Closed December 9, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.0 million each.
Who has been funded under PAR-25-438?
NIH RePORTER lists 8 projects funded under PAR-25-438 in fiscal 2026, at 8 institutions. The most were at University of Cincinnati, Boston Children's Hospital, Henry Ford Health + Michigan State University Health Sciences.
Who has won Oral Diseases and Disorders Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Regents of the University of California, San Francisco, University of Southern California. The program made 2,263 awards worth $1.9 billion in that time.
Similar open grants
- Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional)
- Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)
- Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
- Health and Extreme Weather Solutions-Focused Research Hubs (U54 - Clinical Trial Optional)
- George M. O’Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
- Limited Competition: The NHGRI Analysis, Visualization, and Informatics Lab-space (AnVIL) (U54 Clinical Trial Not Allowed)